192 related articles for article (PubMed ID: 35354467)
21. FOXA1 antagonizes EZH2-mediated CDKN2A repression in carcinogenesis.
Zhang Y; Tong T
Biochem Biophys Res Commun; 2014 Oct; 453(1):172-8. PubMed ID: 25264199
[TBL] [Abstract][Full Text] [Related]
22. p16/MTS1/INK4A suppresses prostate cancer by both pRb dependent and independent pathways.
Steiner MS; Wang Y; Zhang Y; Zhang X; Lu Y
Oncogene; 2000 Mar; 19(10):1297-306. PubMed ID: 10713671
[TBL] [Abstract][Full Text] [Related]
23. G1 arrest by p16INK4A uncouples growth from cell cycle progression in leukemia cells with deregulated cyclin E and c-Myc expression.
Ausserlechner MJ; Obexer P; Geley S; Kofler R
Leukemia; 2005 Jun; 19(6):1051-7. PubMed ID: 15800668
[TBL] [Abstract][Full Text] [Related]
24. CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus.
Bernard D; Martinez-Leal JF; Rizzo S; Martinez D; Hudson D; Visakorpi T; Peters G; Carnero A; Beach D; Gil J
Oncogene; 2005 Aug; 24(36):5543-51. PubMed ID: 15897876
[TBL] [Abstract][Full Text] [Related]
25. Low p16
Graham MK; Principessa L; Antony L; Meeker AK; Isaacs JT
Prostate; 2017 Mar; 77(4):374-384. PubMed ID: 27859428
[TBL] [Abstract][Full Text] [Related]
26. Knockdown of AGR2 induces cellular senescence in prostate cancer cells.
Hu Z; Gu Y; Han B; Zhang J; Li Z; Tian K; Young CY; Yuan H
Carcinogenesis; 2012 Jun; 33(6):1178-86. PubMed ID: 22467239
[TBL] [Abstract][Full Text] [Related]
27. Tumor suppressor p16INK4A is necessary for survival of cervical carcinoma cell lines.
McLaughlin-Drubin ME; Park D; Munger K
Proc Natl Acad Sci U S A; 2013 Oct; 110(40):16175-80. PubMed ID: 24046371
[TBL] [Abstract][Full Text] [Related]
28. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis.
Song H; Zhang B; Watson MA; Humphrey PA; Lim H; Milbrandt J
Oncogene; 2009 Sep; 28(37):3307-19. PubMed ID: 19597465
[TBL] [Abstract][Full Text] [Related]
29. Cdkn2a suppresses metastasis in squamous cell carcinomas induced by the gain-of-function mutant p53(R172H).
Li Z; Gonzalez CL; Wang B; Zhang Y; Mejia O; Katsonis P; Lichtarge O; Myers JN; El-Naggar AK; Caulin C
J Pathol; 2016 Oct; 240(2):224-34. PubMed ID: 27447534
[TBL] [Abstract][Full Text] [Related]
30. KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer.
Mastoraki S; Balgkouranidou I; Tsaroucha E; Klinakis A; Georgoulias V; Lianidou E
Mol Oncol; 2021 Sep; 15(9):2412-2422. PubMed ID: 33159839
[TBL] [Abstract][Full Text] [Related]
31. PTEN controls β-cell regeneration in aged mice by regulating cell cycle inhibitor p16ink4a.
Zeng N; Yang KT; Bayan JA; He L; Aggarwal R; Stiles JW; Hou X; Medina V; Abad D; Palian BM; Al-Abdullah I; Kandeel F; Johnson DL; Stiles BL
Aging Cell; 2013 Dec; 12(6):1000-11. PubMed ID: 23826727
[TBL] [Abstract][Full Text] [Related]
32. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice.
Krimpenfort P; Quon KC; Mooi WJ; Loonstra A; Berns A
Nature; 2001 Sep; 413(6851):83-6. PubMed ID: 11544530
[TBL] [Abstract][Full Text] [Related]
33. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression.
Ding Z; Wu CJ; Chu GC; Xiao Y; Ho D; Zhang J; Perry SR; Labrot ES; Wu X; Lis R; Hoshida Y; Hiller D; Hu B; Jiang S; Zheng H; Stegh AH; Scott KL; Signoretti S; Bardeesy N; Wang YA; Hill DE; Golub TR; Stampfer MJ; Wong WH; Loda M; Mucci L; Chin L; DePinho RA
Nature; 2011 Feb; 470(7333):269-73. PubMed ID: 21289624
[TBL] [Abstract][Full Text] [Related]
34. Loss of p16(INK4a) is associated with reduced patient survival in soft tissue tumours, and indicates a senescence barrier.
Knösel T; Altendorf-Hofmann A; Lindner L; Issels R; Hermeking H; Schuebbe G; Gibis S; Siemens H; Kampmann E; Kirchner T
J Clin Pathol; 2014 Jul; 67(7):592-8. PubMed ID: 24747207
[TBL] [Abstract][Full Text] [Related]
35. p16INK4a suppresses BRCA1-deficient mammary tumorigenesis.
Scott A; Bai F; Chan HL; Liu S; Ma J; Slingerland JM; Robbins DJ; Capobianco AJ; Pei XH
Oncotarget; 2016 Dec; 7(51):84496-84507. PubMed ID: 27811360
[TBL] [Abstract][Full Text] [Related]
36. Lysine Demethylase 6B Regulates Prostate Cancer Cell Proliferation by Controlling c-MYC Expression.
Yıldırım-Buharalıoğlu G
Mol Pharmacol; 2022 Feb; 101(2):106-119. PubMed ID: 34862309
[TBL] [Abstract][Full Text] [Related]
37. KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function.
Gala K; Li Q; Sinha A; Razavi P; Dorso M; Sanchez-Vega F; Chung YR; Hendrickson R; Hsieh JJ; Berger M; Schultz N; Pastore A; Abdel-Wahab O; Chandarlapaty S
Oncogene; 2018 Aug; 37(34):4692-4710. PubMed ID: 29755131
[TBL] [Abstract][Full Text] [Related]
38. Identification of a Rare Novel KMT2C Mutation That Presents with Schizophrenia in a Multiplex Family.
Chen CH; Huang A; Huang YS; Fang TH
J Pers Med; 2021 Nov; 11(12):. PubMed ID: 34945726
[TBL] [Abstract][Full Text] [Related]
39. Intrinsic cooperation between p16INK4a and p21Waf1/Cip1 in the onset of cellular senescence and tumor suppression in vivo.
Takeuchi S; Takahashi A; Motoi N; Yoshimoto S; Tajima T; Yamakoshi K; Hirao A; Yanagi S; Fukami K; Ishikawa Y; Sone S; Hara E; Ohtani N
Cancer Res; 2010 Nov; 70(22):9381-90. PubMed ID: 21062974
[TBL] [Abstract][Full Text] [Related]
40. miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition.
Zhao Z; Zhao S; Luo L; Xiang Q; Zhu Z; Wang J; Liu Y; Luo J
Br J Cancer; 2021 Mar; 124(5):982-994. PubMed ID: 33239676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
